Atossa Therapeutics, Inc.
ATOS
Price:
$0.7595
Market Cap:
$98.11M
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized COVID-19 patients; AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. It has a research agreement with Dana-Farber Cance...[Read more]
Industry
Biotechnology
IPO Date
2012-11-08
Stock Exchange
NASDAQ
Ticker
ATOS
PE Ratio
[-3.30]
ROE
[-42.83%]
Current Ratio
[9.17]
Dividend Yield
[0%]
Enterprise Value
[40.25M]
Dividend History
The ROE as of December 2025 (TTM) for Atossa Therapeutics, Inc. (ATOS) is -42.83%
According to Atossa Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -42.83%. This represents a change of 293.20% compared to the average of -10.89% of the last 4 quarters.
Atossa Therapeutics, Inc. (ATOS) Historical ROE (quarterly & annually)
How has ATOS ROE performed in the past?
The mean historical ROE of Atossa Therapeutics, Inc. over the last ten years is -117.66%. The current -42.83% ROE has changed -63.59% with respect to the historical average. Over the past ten years (40 quarters), ATOS's ROE was at its highest in in the September 2016 quarter at 3.78%. The ROE was at its lowest in in the December 2015 quarter at -132.60%.
Average
-117.66%
Median
-91.34%
Minimum
-421.20%
Maximum
-14.92%
Atossa Therapeutics, Inc. (ATOS) ROE by Quarter and Year
Discovering the peaks and valleys of Atossa Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 172.93%
Maximum Annual ROE = -14.92%
Minimum Annual Increase = -77.27%
Minimum Annual ROE = -421.20%
| Year | ROE | Change |
|---|---|---|
| 2024 | -35.68% | 7.91% |
| 2023 | -33.06% | 44.67% |
| 2022 | -22.85% | 53.21% |
| 2021 | -14.92% | -77.27% |
| 2020 | -65.62% | -49.92% |
| 2019 | -131.04% | 1.17% |
| 2018 | -129.53% | 10.65% |
| 2017 | -117.06% | -43.07% |
| 2016 | -205.64% | -51.18% |
| 2015 | -421.20% | 172.93% |
Atossa Therapeutics, Inc. (ATOS) Average ROE
How has ATOS ROE performed in the past?
The current ROE of Atossa Therapeutics, Inc. (ATOS) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-30.53%
5-year avg
-34.43%
10-year avg
-117.66%
Atossa Therapeutics, Inc. (ATOS) ROE vs. Peers
How is ATOS’s ROE compared to its peers?
Atossa Therapeutics, Inc.’s ROE is greater than Oncolytics Biotech Inc. (-755.18%), less than Tevogen Bio Holdings Inc. (391.67%), greater than Greenwich LifeSciences, Inc. (-1042.76%), greater than Instil Bio, Inc. (-54.32%), greater than Immix Biopharma, Inc. (-263.55%), greater than Whitehawk Therapeutics Inc (-8.09%), less than Clene Inc. (448.29%), greater than Surrozen, Inc. (-180.14%), greater than Cognition Therapeutics, Inc. (-251.23%), greater than Coya Therapeutics, Inc. (-86.00%),
| Company | ROE | Market cap |
|---|---|---|
| -755.18% | $98.42M | |
| 391.67% | $83.79M | |
| -1042.76% | $121.82M | |
| -54.32% | $77.28M | |
| -263.55% | $162.49M | |
| -8.09% | $120.65M | |
| 448.29% | $58.52M | |
| -180.14% | $156.26M | |
| -251.23% | $129.50M | |
| -86.00% | $99.69M |
Build a custom stock screener for Atossa Therapeutics, Inc. (ATOS) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Atossa Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Atossa Therapeutics, Inc. (ATOS) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Atossa Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Atossa Therapeutics, Inc.'s ROE?
How is the ROE calculated for Atossa Therapeutics, Inc. (ATOS)?
What is the highest ROE for Atossa Therapeutics, Inc. (ATOS)?
What is the 3-year average ROE for Atossa Therapeutics, Inc. (ATOS)?
What is the 5-year average ROE for Atossa Therapeutics, Inc. (ATOS)?
How does the current ROE for Atossa Therapeutics, Inc. (ATOS) compare to its historical average?